The use of B-cell targeted therapies for the treatment of systemic lupus erythematosus (SLE) has generated great interest owing to the multiple pathogenic roles carried out by B cells in this disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback